このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

進行性尿路上皮癌における免疫療法薬、ペンブロリズマブ (MK-3475) へのタゼメトスタットの追加の試験

2026年11月11日 更新者:National Cancer Institute (NCI)

進行性尿路上皮がんにおけるタゼメトスタットとペムブロリズマブ (MK-3475) のパイロット研究

This phase I/II trial studies the side effects and best dose of tazemetostat and how well it works when given together with pembrolizumab in treating patients with urothelial carcinoma that has spread to nearby tissue or lymph nodes (locally advanced ) or from where it first started (primary site) to other places in the body (metastatic). Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tazemetostat and pembrolizumab may work better in treating patients with urothelial carcinoma compared to pembrolizumab without tazemetostat.

調査の概要

状態

積極的、募集していない

条件

介入・治療

詳細な説明

PRIMARY OBJECTIVE:

I. To conduct a safety lead-in phase that identifies the safe recommended phase II dose for combination tazemetostat and pembrolizumab (MK-3475).

SECONDARY OBJECTIVES:

I. To assess the safety and tolerability of pembrolizumab (MK-3475) in combination with tazemetostat.

II. To evaluate the objective disease response rate of combination tazemetostat and pembrolizumab (MK-3475) in patients with advanced urothelial carcinoma that is cisplatin resistant (Arm A) or cisplatin ineligible (Arm B).

III. To evaluate the progression free survival to combination tazemetostat and pembrolizumab (MK-3475) in patients with advanced urothelial carcinoma that is cisplatin resistant (Arm A) or cisplatin ineligible (Arm B).

IV. To evaluate immune-related response using tumor response by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) in combination tazemetostat and pembrolizumab (MK-3475) in patients with advanced urothelial carcinoma that is cisplatin resistant (Arm A) or cisplatin ineligible (Arm B) based on irRECIST criteria.

CORRELATIVE OBJECTIVES:

I. To determine if EZH2 and H3K27me3 chromatin methylation determines disease response to EZH2 and PD1 inhibition in metastatic urothelial carcinoma by analyzing baseline tissue samples.

II. To determine if mutations in genes associated with histone methylation determine disease response to EZH2 and PD1 inhibition in metastatic urothelial carcinoma by analyzing baseline tissue samples.

III. To identify the immune response (T cell phenotypes), T-cell clonality with comparison to T-cell infiltrating lymphocytes and neoantigen profile of responsive and resistant urothelial carcinoma treated with combination anti-PD1 and EZH2i by analyzing blood and tissue samples throughout the study.

OUTLINE:

Patients receive tazemetostat orally (PO) twice daily (BID) on days 1-21 and pembrolizumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial and undergo collection of blood samples on study.

After completion of study treatment, patients are followed up every 3 months for 1 year.

研究の種類

介入

入学 (推定)

30

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Arizona
      • Phoenix、Arizona、アメリカ、85054
        • Mayo Clinic Hospital in Arizona
      • Scottsdale、Arizona、アメリカ、85259
        • Mayo Clinic in Arizona
    • Connecticut
      • Derby、Connecticut、アメリカ、06418
        • Smilow Cancer Hospital-Derby Care Center
      • Fairfield、Connecticut、アメリカ、06824
        • Smilow Cancer Hospital Care Center-Fairfield
      • Guilford、Connecticut、アメリカ、06437
        • Smilow Cancer Hospital Care Center - Guilford
      • Hartford、Connecticut、アメリカ、06105
        • Smilow Cancer Hospital Care Center at Saint Francis
      • New Haven、Connecticut、アメリカ、06520
        • Yale University
      • New Haven、Connecticut、アメリカ、06510
        • Smilow Cancer Center/Yale-New Haven Hospital
      • North Haven、Connecticut、アメリカ、06473
        • Yale-New Haven Hospital North Haven Medical Center
      • Orange、Connecticut、アメリカ、06477
        • Smilow Cancer Hospital-Orange Care Center
      • Torrington、Connecticut、アメリカ、06790
        • Smilow Cancer Hospital-Torrington Care Center
      • Trumbull、Connecticut、アメリカ、06611
        • Smilow Cancer Hospital Care Center-Trumbull
      • Waterbury、Connecticut、アメリカ、06708
        • Smilow Cancer Hospital-Waterbury Care Center
      • Waterford、Connecticut、アメリカ、06385
        • Smilow Cancer Hospital Care Center - Waterford
    • Florida
      • Jacksonville、Florida、アメリカ、32224-9980
        • Mayo Clinic in Florida
    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • Northwestern University
    • Kansas
      • Fairway、Kansas、アメリカ、66205
        • University of Kansas Clinical Research Center
      • Hays、Kansas、アメリカ、67601
        • HaysMed
      • Lawrence、Kansas、アメリカ、66044
        • Lawrence Memorial Hospital
      • Olathe、Kansas、アメリカ、66061
        • The University of Kansas Cancer Center - Olathe
      • Overland Park、Kansas、アメリカ、66210
        • University of Kansas Cancer Center-Overland Park
      • Pittsburg、Kansas、アメリカ、66762
        • Mercy Hospital Pittsburg
      • Salina、Kansas、アメリカ、67401
        • Salina Regional Health Center
      • Topeka、Kansas、アメリカ、66606
        • University of Kansas Health System Saint Francis Campus
      • Westwood、Kansas、アメリカ、66205
        • University of Kansas Hospital-Westwood Cancer Center
    • Kentucky
      • Lexington、Kentucky、アメリカ、40536
        • University of Kentucky/Markey Cancer Center
    • Minnesota
      • Rochester、Minnesota、アメリカ、55905
        • Mayo Clinic in Rochester
    • Missouri
      • Kansas City、Missouri、アメリカ、64154
        • University of Kansas Cancer Center - North
      • Kansas City、Missouri、アメリカ、64108
        • University Health Truman Medical Center
      • Lee's Summit、Missouri、アメリカ、64064
        • University of Kansas Cancer Center - Lee's Summit
      • North Kansas City、Missouri、アメリカ、64116
        • University of Kansas Cancer Center at North Kansas City Hospital
    • New Hampshire
      • Lebanon、New Hampshire、アメリカ、03756
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
    • Pennsylvania
      • Pittsburgh、Pennsylvania、アメリカ、15232
        • UPMC Hillman Cancer Center
    • Ontario
      • Toronto、Ontario、カナダ、M5G 2M9
        • University Health Network-Princess Margaret Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Patients must have pathologically confirmed urothelial carcinoma

    • Note: Patients with mixed histology (with predominant urothelial carcinoma) are eligible
  • Patients must have locally advanced or metastatic disease with either:

    • Arm A: Disease progression during or following (within 12 months) platinum-based chemotherapy (cisplatin or carboplatin)

      • Note: No minimum number of cycles on platinum-based chemotherapy are required. Patients who have had multiple rounds of platinum-based chemotherapy with events of intermittent progressive disease (PD) are eligible as long as progression has been confirmed while on or within 12 months from platinum based therapy OR
    • Arm B: Platinum ineligible status (i.e., patients unable to receive platinum-containing chemotherapy, in the opinion of the treating investigator, regardless of PD-L1 status) or chemotherapy ineligible status (i.e., patients unable to receive treatment with any chemotherapy, in the opinion of the treating investigator, regardless of PD-L1 status)

      • Note: The eligible patient population for Arm B was revised in protocol amendment 10 from 'cisplatin ineligible patients with PD-L1 positive disease' to 'platinum ineligible patients (i.e., unable to receive platinum-containing chemotherapy, in the opinion of the treating investigator, regardless of PD-L1 status) or chemotherapy ineligible patients (i.e., unable to receive treatment with any chemotherapy, in the opinion of the treating investigator, regardless of PD-L1 status).' This revision was made to align with the updated United States (U.S.) Food and Drug Administration (FDA) indications for pembrolizumab (MK-3475) that were released in August of 2021 for patients with locally advanced or metastatic urothelial carcinoma
  • All patients must have measurable disease in accordance with RECIST criteria version (v) 1.1

    • Note: radiological evaluation should occur within 28 days prior to study registration
  • Patients must be naive to prior PD-L1 or EZH2 inhibitors

    • Note: patients in Arm A should have received platinum-based chemotherapy only
  • Age >= 18 years

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2

  • Leukocytes >= 3000/mcL (performed within 14 days prior to registration)

  • Absolute neutrophil count (ANC) >= 1500/mcL (performed within 14 days prior to registration)

  • Platelets >= 100 000/mcL (performed within 14 days prior to registration)

  • Hemoglobin >= 9 g/dL or >= 4.9 mmol/L (performed within 14 days prior to registration)

  • Creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance (CrCl) >= 30 mL/min for patient with creatinine levels > 1.5 x institutional ULN (performed within 14 days prior to registration)

    • Creatinine clearance (CrCl) should be calculated per institutional standard
    • Glomerular filtration rate (GFR) can also be used in place of creatinine or CrCl
  • Total bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for patients with total bilirubin levels > 1.5 x ULN (performed within 14 days prior to registration)

  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN OR =< 5 x ULN for patients with liver metastases (performed within 14 days prior to registration)

  • International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants (performed within 14 days prior to registration)

  • Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants (performed within 14 days prior to registration)

  • The effects of pembrolizumab (MK-3475) and tazemetostat on the developing human fetus are unknown. For this reason and because PD-1 inhibitors as well as EZH2 inhibitors are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation

    • Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
    • Female patients of childbearing/reproductive potential must be willing to use an adequate method of contraception, for the course of the study through 6 months for females and 3 months for males, respectively, after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient
    • Male patients of reproductive potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 3 months after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient
    • Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Participants who have the ability to understand and the willingness to sign an Institutional Review Board (IRB) approved written informed consent document are eligible OR Participants with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver are eligible

  • Human immunodeficiency virus (HIV)-infected patients who do not have a history of Kaposi sarcoma and/or Multicentric Castleman Disease, who are on effective anti-retroviral therapy, and who have undetectable viral load within 6 months are eligible for this trial

Exclusion Criteria:

  • Patients with disease that is suitable for local therapy administered with curative intent are not eligible

  • Patients who have had chemotherapy, targeted small molecule therapy, or radiotherapy within 4 weeks prior to entering the study are not eligible

  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1 per Common Terminology Criteria for Adverse Events [CTCAE] v.5 ) are not eligible

    • Note: patients with =< grade 2 neuropathy or =< grade 2 alopecia or =< grade 3 audiometric hearing loss are an exception to this criterion and may qualify for the study
    • Note: if patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
  • Patients are not eligible who are currently participating and receiving study therapy or have participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment

  • Patients who have received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including granulocyte colony-stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF], or recombinant erythropoietin) within 4 weeks prior to the first dose of treatment are not eligible

  • Patients with a diagnosis of immunodeficiency or are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment are not eligible

    • Note: the use of physiologic doses of corticosteroids may be approved after consultation with the study principal investigator (PI)
  • Patients with thrombocytopenia, neutropenia, or anemia of grade 3 (per CTCAE 5.0 criteria) are not eligible

  • Patients with abnormalities known to be associated with MDS (e.g. del 5q, chr 7 abn) and myeloproliferative neoplasms (MPN, e.g. JAK2 V617F) observed in cytogenetic testing and deoxyribonucleic acid (DNA) sequencing are not eligible

  • Patients with an ongoing or untreated hematologic malignancy or myeloproliferative disorder, or a prior history of a hematologic malignancy or myeloproliferative disorder are not eligible. (Examples of excluded malignancies/disorders include but are not limited to myelodysplastic syndrome [MDS], T cell lymphoblastic lymphoma (T-LBL), T cell acute lymphoblastic leukemia (T-ALL), and any other myeloid or lymphoid malignancy)

  • Patients who have received prior PD-L1/PD-1/PD-L2 or EZH2 inhibitor therapy are not eligible

  • Patients who have had a prior monoclonal antibody within 4 weeks prior to study day 1 are not eligible

  • Patients must be disease-free of prior invasive malignancies for > 5 years, with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. If there is a history of prior malignancy, patients must not be receiving other specific treatment for that cancer

  • Patients with known brain metastases or carcinomatous meningitis are excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events

    • Note: patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging using the identical imaging modality for each assessment, either magnetic resonance imaging (MRI) or computed tomography (CT) scan, for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment
  • Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab (MK-3475) or tazemetostat are not eligible

  • Patients with an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs) are not eligible

    • Note: replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
  • Patients with a history of (non-infectious) pneumonitis that required steroids or current pneumonitis are not eligible

  • Patients with a prolongation of corrected QT interval (Fridericia's correction formula [QTcF]) of > 450 msec are not eligible

  • Patients with major surgery within 3 weeks before the first dose of study drugs

    • Note: minor surgery (e.g. minor biopsy of an extracranial site, central venous catheter placement, shunt revision) has no restriction
  • Patients must not have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator

  • Patients receiving any medications or substances that are strong or moderate inhibitors or inducers of CYP3A =< 14 days prior to study treatment are not eligible

    • Note: The study team should check a frequently-updated medical reference for a list of drugs to avoid or minimize use of. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
  • Patients who are unable to take oral medication OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, vomiting) that might impair the bioavailability of tazemetostat are not eligible

  • Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled arterial hypertension, stroke within 6 months prior to starting study treatment, or psychiatric illness/social situations that would limit compliance with study requirements are not eligible

  • Pregnant women are excluded from this study because pembrolizumab (MK-3475) and tazemetostat are agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with pembrolizumab (MK-3475) and tazemetostat, breastfeeding should be discontinued if the mother is treated with pembrolizumab (MK-3475) or tazemetostat

    • Pembrolizumab (MK-3475) may have adverse effects on a fetus in utero. Furthermore, it is not known if pembrolizumab (MK-3475) has transient adverse effects on the composition of sperm
    • Patients are excluded from this study if pregnant or breastfeeding, or expecting to conceive or father children (or donate sperm) within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of trial treatment
  • Patients with a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection are not eligible

    • Note: no testing for hepatitis B and hepatitis C is required unless mandated by local health authority
  • Patients who have received a live vaccine within 30 days of planned treatment start are not eligible

    • Note: seasonal flu vaccines that do not contain live virus are permitted

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment (tazemetostat, pembrolizumab)

Patients receive tazemetostat PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout the trial and undergo collection of blood samples on study.

Undergo CT

他の名前:
  • CT
  • 猫
  • CATスキャン
  • コンピューター断層撮影
  • コンピュータ化されたアキシャルトモグラフィー
  • CTスキャン
  • トモグラフィー
  • コンピューター断層撮影 (手順)
  • コンピューター断層撮影 (CT) スキャン
  • 診断CATスキャン
  • 診断CATスキャンサービスタイプ

Undergo MRI

他の名前:
  • MRI
  • 磁気共鳴
  • 磁気共鳴画像スキャン
  • 医用画像、磁気共鳴 / 核磁気共鳴
  • 氏
  • MRイメージング
  • MRI スキャン
  • NMRイメージング
  • NMRI
  • 核磁気共鳴イメージング
  • 磁気共鳴画像法 (MRI)
  • sMRI
  • 磁気共鳴画像法(手順)
  • 構造MRI

Given IV

他の名前:
  • キイトルーダ
  • MK-3475
  • ランブロリズマブ
  • SCH 900475
  • MK3475
  • SCH-900475
  • BCD-201
  • ペムブロリズマブ バイオシミラー BCD-201
  • ペムブロリズマブ バイオシミラー QL2107
  • QL2107
  • GME751
  • ペムブロリズマブ バイオシミラー GME751
  • MK 3475
  • SCH900475
  • ペムブロリズマブ バイオシミラー RPH-075
  • RPH075
  • RPH-075
  • ペンブロリズマブバイオシミラーSB27
  • SB 27
  • SB-27
  • SB27

Undergo collection of blood samples

他の名前:
  • 生物学的サンプルの収集
  • 採取された生体試料
  • 標本収集
  • サンプル収集

Given PO

他の名前:
  • EPZ-6438
  • E7438
  • EPZ6438
  • E 7438
  • E-7438
  • EPZ 6438

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Recommended phase 2 dose (RP2D) of tazemetostat in combination with pembrolizumab
時間枠:Up to 21 days following the first dose of tazemetostat

The 3+3 rule will be used to define the RP2D, such that for each cohort, the highest level in which =< 1 out of 6 patients experienced dose limiting toxicity (DLT), at or below the maximum administered dose, would constitute the RP2D. If =< 1 of 6 patients experienced DLTs at the maximum administered dose, then the maximum administered dose will be declared RP2D for that cohort.

Up to 21 days following the first dose of tazemetostat

二次結果の測定

結果測定
メジャーの説明
時間枠
Incidence of adverse events
時間枠:Up to 30 days after treatment discontinuation

Will be assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 5. All adverse events will be summarized as to type, grade, timing, frequency and attribution using frequencies and percentages

Up to 30 days after treatment discontinuation
Objective response rate (ORR)
時間枠:Up to 1 year

Response rates will be summarized in each cohort by proportions and 95% exact confidence intervals.

Up to 1 year
Progression free survival
時間枠:From start of treatment to time of progression or death, whichever occurs first, assessed up to 1 year

Will be summarized using the Kaplan-Meier product limit curve.

From start of treatment to time of progression or death, whichever occurs first, assessed up to 1 year
Response rate
時間枠:Up to 1 year

Assessed by immune related Response Evaluation Criteria in Solid Tumors (irRECIST) for investigational purposes. Tumor response by irRECIST is defined as an immune-related partial response or complete response over a period of at least 4 weeks. Will define immune-related clinical benefit rate as immune-related stable disease, partial response, or complete response. Response rate by irRECIST will be summarized in each cohort by proportions and 95% exact confidence intervals.

Up to 1 year

その他の成果指標

結果測定
メジャーの説明
時間枠
EZH2 and H3K27me3 chromatin methylation and mutations in genes associated with histone methylation
時間枠:Baseline

Will determine if EZH2, H3K27me3 and mutations in genes associated with histone methylation determine disease response to EZH2 and PD1. Each gene will be related to response using Fisher's exact test.

Baseline
Immune response
時間枠:Up to 1 year

Will be analyzed by comparing the baseline tissue with follow-up tissue either at cycle 3 or end of study using a signed rank test or a paired t-test.

Up to 1 year

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Maha H Hussain、University Health Network Princess Margaret Cancer Center LAO

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年11月18日

一次修了 (推定)

2027年6月30日

研究の完了 (推定)

2027年6月30日

試験登録日

最初に提出

2019年2月25日

QC基準を満たした最初の提出物

2019年2月25日

最初の投稿 (実際)

2019年2月26日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • NCI-2019-01035
  • P30CA060553 (米国 NIH グラント/契約)
  • NCI-2019-01035 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
  • ETCTN 10183
  • 10183 (その他の識別子:CTEP)
  • 10183 (その他の識別子:University Health Network Princess Margaret Cancer Center LAO)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。